Basilea Pharmaceutica

Antibiotics and Infectious diseasesDermatologicalsOncology

Basilea Pharmaceutica

Basilea Pharmaceutica (SIX: BSLN) is headquartered in Basel, Switzerland.

Basilea Pharmaceutica (SIX: BSLN) is headquartered in Basel, Switzerland.

Through its fully integrated R&D operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Basilea has a broad pipeline of innovative drugs with well differentiated and competitive profiles to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors.

Basilea'’s anti-infectives isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic BAL30072 and the oncology compound BAL101553 are in clinical phase I. Toctino (oral alitretinoin) for chronic hand eczema is marketed by Stiefel and its distributors in Austria, Canada, Denmark, Finland, France, Germany, Iceland, Israel, Italy, Norway, Switzerland and the UK. In addition, the drug is approved in 15 further European countries.

Basilea’'s research emphasis is placed on focused optimization of successful compound classes addressing established targets (e.g. beta-lactams) as well as pursuing novel targets through the discovery of drug leads by screening of compound libraries and structure-based drug design.


Latest Articles

Who's Who

Back to top